Alzheimer's Disease Competitive Landscape and Clinical Trial Analysis Report 2026: More Than 200 Companies and 240 Therapies Assessed
Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Alzheimer's Disease - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering.
The "Alzheimer's Disease - Competitive Landscape and Clinical Trial Analysis, 2026" report provides a comprehensive global assessment of more than 200 companies and 240 marketed and investigational Alzheimer's disease therapies. The research evaluates products by development stage, molecule type, route of administration, therapeutic approach and clinical status. It also examines inactive pipeline assets, unmet medical needs, strategic collaborations, licensing agreements, acquisitions and emerging technologies shaping the Alzheimer's disease treatment landscape.
Global Alzheimer's Disease Market and Clinical Overview
Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia among adults aged 65 years and older. Its pathology is associated with amyloid-beta plaque accumulation, tau neurofibrillary tangles and progressive neuronal degeneration. Disease risk reflects genetic, cardiovascular, metabolic, environmental and age-related factors. The APOE ?4 allele is a major risk factor for late-onset Alzheimer's disease, while mutations in APP, PSEN1 and PSEN2 are associated with rare early-onset forms.
Diagnosis incorporates medical and family history, cognitive and functional assessment, neurological examination, laboratory testing and biomarker evaluation. Current treatment includes symptomatic therapies such as donepezil, rivastigmine and galantamine, alongside disease-modifying amyloid-targeting medicines for eligible patients with early Alzheimer's disease and confirmed amyloid pathology.
Notable Alzheimer's Disease Pipeline and Industry Developments
Marketed Alzheimer's Disease Therapies
Eli Lilly's Kisunla is an intravenous amyloid-targeting therapy approved for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease and confirmed amyloid pathology. The FDA approved Kisunla in July 2024 based on the Phase III TRAILBLAZER-ALZ 2 study. Its safety profile includes risks of amyloid-related imaging abnormalities and infusion-related reactions.
LEQEMBI, developed by Eisai and Biogen, is a humanized IgG1 monoclonal antibody targeting soluble and insoluble aggregated amyloid-beta. Following accelerated approval in January 2023, LEQEMBI received traditional FDA approval in July 2023 based on confirmatory findings from the Phase III CLARITY AD trial. It is indicated for patients with early Alzheimer's disease and confirmed amyloid-beta pathology.
Selected Alzheimer's Disease Pipeline Therapies
Alzheimer's Disease Competitive Landscape Assessment
The report compares companies, therapies and technologies across the Alzheimer's disease pipeline. Its commercial analysis covers company-to-company collaborations, academic partnerships, licensing transactions, mergers and acquisitions, and deal-value trends. The assessment also identifies inactive programs and areas of unmet need across symptomatic and disease-modifying treatment strategies.
The clinical trial analysis evaluates studies by status, development phase, therapeutic category, participant age, enrollment, anticipated completion year and endpoint status. Clinical trial design is assessed by allocation, intervention model and masking. Sponsor and geographic analyses review leading trial sponsors, development stages, country-level clinical activity and regional therapy distribution.
Key Questions Addressed
Companies Featured in the Report
Key companies include AriBio, Eisai, Biogen, Acadia Pharmaceuticals, Johnson & Johnson, AC Immune, Sanofi, Alnylam Pharmaceuticals, Eli Lilly and Company, AbbVie, F. Hoffmann-La Roche, Halia Therapeutics, Ono Pharmaceutical, Spinogenix, Cenna Biosciences, Akeso Biopharma, Regeneron Pharmaceuticals, NSC-Therapeutics, Lexeo Therapeutics, Therini Bio, Bristol Myers Squibb, SciNeuro Pharmaceuticals, ProMIS Neurosciences and Denali Therapeutics.
Products Covered
Major products assessed include Kisunla, LEQEMBI, AR1001, ACP-204, JNJ-64042056, SAR448851, mivelsiran, mevidalen, ABBV-1758, RG6627, HT-4253, ONO-2020, tazbentetol, E2814, 8M2D, AK152, ALN-5288, NSC001, LX1001, THN391, irafamdastat, SNP318, PMN310, DNL628, DNL921, SNP234, moponetug, LY3439539, RG6289 and RG6102.
The report offers pharmaceutical companies, biotechnology developers, investors, clinical research organizations and healthcare stakeholders a detailed view of the global Alzheimer's disease competitive landscape, clinical trial environment and evolving therapeutic pipeline in 2026.
Key Topics Covered:
Introduction
Executive Summary
Alzheimer's Disease: Overview
Alzheimer's Disease -Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Alzheimer's Disease: Company and Product Profiles (Marketed Therapies)
Eli Lilly and Company
Kisunla
Alzheimer's Disease: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
AriBio
AR1001
Mid Stage Products (Phase II)
Sanofi
SAR448851
Early Stage Products (Phase I)
F. Hoffmann-La Roche
RG6627
Preclinical Stage Products
Discovery Stage Products
Unknown Stage Products
Therapeutic Assessment
Clinical Trial Assessment
Clinical Trial Analysis
Clinical Trial Design Analysis
Sponsor and Geographical Analysis
Inactive Products
Alzheimer's Disease- Unmet needs
Alzheimer's Disease - Market drivers and barriers
Appendix
List of Tables
Table 1 Total Products for Alzheimer's Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Assessment by Status
Table 13 Assessment by Status and Phase
Table 14 Assessment by End Point Status
Table 15 Assessment of Enrolled Participants by Age
Table 16 Assessment by Study Completion Year
Table 17 Assessment by Primary Purpose of Clinical Trials
Table 18 Assessment by Allocation of Clinical Trials
Table 19 Assessment by Interventional Model of Clinical Trials
Table 20 Assessment by Masking of Clinical Trials
Table 21 Assessment by Enrolled participants by Status
Table 22 Assessment by Top Sponsors
Table 23 Assessment by Countries and Stage of Development
Table 24 Inactive Products
List of Figures
Figure 1 Total Products for Alzheimer's Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Assessment by Status
Figure 13 Assessment by Status and Phase
Figure 14 Assessment by End Point Status
Figure 15 Assessment of Enrolled Participants by Age
Figure 16 Assessment by Study Completion Year
Figure 17 Assessment by Primary Purpose of Clinical Trials
Figure 18 Assessment by Allocation of Clinical Trials
Figure 19 Assessment by Interventional Model of Clinical Trials
Figure 20 Assessment by Masking of Clinical Trials
Figure 21 Assessment by Enrolled participants by Status
Figure 22 Assessment by Top Sponsors
Figure 23 Assessment by Countries and Stage of Development
Figure 24 Inactive Products
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/x0q0cw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.